Lung Cancer

A chemotherapy shortage is resulting in altered treatment plans for many patients with cancer. CURE® spoke with experts about what that means for patients — and what they can do about it.

Treatment with a CAR-M cell therapy plus Keytruda is being assessed in a phase 1 study in patients with HER2-overexpressed tumors.

Studies show that eating a high-fat meal with Alecensa can benefit patients with lung cancer throughout recovery.

An expert discusses the ongoing SPARK trial for KRASG12-mutant non-small cell lung cancer, and what she hopes for the future of this patient population.

A survey of cancer centers found that the majority of large centers are facing cisplatin and carboplatin shortages, and some are changing or delaying treatment because of it.

From Shannen Doherty’s announcement that her breast cancer spread to her brain to a nonprofit being established in memory of the late YouTuber, Technoblade, here’s what’s happening in the oncology space this week.

Patients with non-small cell lung cancer who cleared 50% or more of cancerous DNA from their blood by their fourth treatment cycle tended to have better outcomes on maintenance therapy, research showed.

Tumor treating fields therapy “is a potentially paradigm-shifting new treatment modality” for metastatic non-small cell lung cancer, says Dr. Ticiana Leal.

Adding Keytruda to pre-surgical chemotherapy then giving it again after surgery improved event-free survival and pathologic complete response in patients with early-stage lung cancer.

The agency accepted a New Drug Application for repotrectinib, a TKI for the treatment of patients with locally advanced or metastatic non-small cell lung cancer.

Watch Dr. Jyoti Malhotra and Ken Culver answer questions about the future of the disease during the CURE® Educated Patient® Lung Cancer Summit.

Work is underway in the global phase 3 HARMONi study evaluating the combination of ivonescimab and chemotherapy in the treatment of patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer.

Watch Dr. Jyoti Malhotra, from City of Hope, discuss advancements in advanced non-small cell lung cancer during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Erminia Massarelli, from City of Hope National Medical Center, discuss advancements in early-stage non-small cell disease during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Ravi Salgia, from City of Hope, discuss advancements in small cell lung cancer during the CURE® Educated Patient® Lung Cancer Summit.

After being diagnosed with a rare form of cancer — and seeing a clinician who did not know how to treat me — I learned the importance of asking questions to my providers and advocating for myself

Watch Dr. Ed Kim, Dr. Jyoti Malhotra and Terri Conneran answer questions about targeted therapy during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Jyoti Malhotra, from City of Hope Orange County, discuss targeted therapy, during the CURE® Educated Patient® Lung Cancer Summit.

Tagrisso plus chemotherapy improved progression-free survival in patients with EGFR-mutated, locally advanced or metastatic non-small cell lung cancer, according to high-level results from a phase 3 trial.

Watch an expert discuss biomarker testing during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Thomas Waddington and Dr. Percy Lee answer questions about diagnostic and radiation advances during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Percy Lee, from City of Hope, discuss radiation advances during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Thomas Waddington, from City of Hope National Medical Center, discuss the past and future of bronchoscopy during the CURE® Educated Patient® Lung Cancer Summit.

The phase 3 HARMONi trial recently kicked off, studying ivonescimab plus chemotherapy for EGFR-mutant non-small cell lung cancer.

The benefit derived from Tyvyt plus chemotherapy was present regardless of whether previously treated patients with EGFR-mutated, non-squamous non-small cell lung cancer also received Byvasda.

I’ve learned that knowledge is the key to fighting cancer. Here are three ways I learn more about my disease.

Deborah Lorick, M.S.N., M.H.A., RN, RNOCN, was the assistant nurse manager on the oncology unit where my husband was a patient. Deborah was always making sure that my husband, my children and I were well cared for.

Many thoughts went through my mind during cancer, and journaling allowed me to organize them and helped me to feel better.

The inflammation associated with lung cancer and depression may impact survival, despite treatments like immunotherapy and targeted therapies.

Supportive care commonly addresses physical symptoms associated with lung cancer and side effects associated with cancer therapy.